This double-blinded clinical trial randomly assigns participants with refractory cutaneous warts to receive either treatment with the human papillomavirus (HPV) vaccine or a placebo to assess the efficacy of HPV vaccination for the treatment of refractory cutaneous warts.
3 Primary · 2 Secondary · Reporting Duration: Quality of life assessments will occur at 0 (baseline), 4, 8, and 24 weeks (primary endpoint)
120 Total Participants · 2 Treatment Groups
Primary Treatment: HPV Vaccine · Has Placebo Group · Phase 2 & 3
Age 18+ · All Participants · 4 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: